Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
New cancer vaccines findings from University of Cambridge described
February 4th, 2009
"The burden of human papillomavirus (HPV)-associated ano-genital disease is significant but the ability to generate HPV virus-like particles by the synthesis and self-assembly in vitro of the major virus coat protein L1 has transformed our prospects for preventing benign and malignant ano-genital disease caused by the common genital HPV types. Peer reviewed journals. Two HPV L1 vaccines have been developed, a quadrivalent HPV 6/11/16/18, and a bivalent HPV 16/18 product," investigators in Cambridge, the United Kingdom report. "Both vaccines are very immunogenic and well tolerated. They have been shown in the various randomized Control trials to be very effective at...
Source: Vaccine Weekly (2009-02-04)
|
